The FDA will limit the vaccine’s availability later this year to older adults and those who may be at risk of severe illness.

The vaccine is expected to remain available for anyone who is at least 65 or who has a medical condition, leaving many Americans ineligible. Here's what we know.

The Consumer Brands Association argues the CPG industry has been ‘putting the transparency into ‘radical transparency’ for ...

The FDA has told vaccine manufacturers to expand the warning labels on their COVID-19 shots with more information about the ...

Mepolizumab has had a bumpy road to arriving at its indication in COPD. An FDA advisory committee in 2018 declined to ...

The approval tees GSK up to challenge Sanofi and Regeneron, which in September 2024 won the first biologic approval for COPD ...

GSK (NYSE:GSK) announced Thursday that the U.S. FDA has further broadened the label for its asthma therapy, approving the ...

New guidelines will favor whole foods like avocados and salmon while cracking down on added sugars, marking the biggest change to food labeling in three decades.

The COPD approval marks the fifth Nucala has received from the FDA, following green lights in severe asthma, chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis and ...

On May 6, 2025, the U.S. Court of Appeals for the Federal Circuit refined the boundaries of injunctive relief under the Hatch ...

While the US Food and Drug Administration has been experiencing recent reorganization and cuts in personnel, the United ...

Rather than waiting for all the patents to expire, they can seek approval for a truncated list of uses – the skinny label – that only includes those that are off-patent. The case focuses on ...